Monoclonal Antibodies Market

Monoclonal Antibodies Market Size By Production Method (In Vivo and In Vitro), By Source (Chimeric, Human, Humanized, and Murine), By End Users (Hospitals, Research Institutes, and Others), Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033

Base Year: 2023 Historical Data: 2020-22
  • Report ID: TBI-13036
  • Published Date: Jul, 2024
  • Pages: 235
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global monoclonal antibodies market was valued at USD 209.44 billion in 2023 and is anticipated to grow at a CAGR of 12.0% from 2024 to 2033. The global monoclonal antibodies market is expected to reach USD 650.49 billion by 2030. The Asia Pacific is expected to grow the fastest during the forecast period. Monoclonal antibodies serve various medical purposes, such as remedying conditions like cancer, autoimmune disorders and infectious diseases. Moreover, they can perform diagnostic functions by identifying particular molecules within human bodies or investigating biological processes for research initiatives. Given their specificity and adaptability, monoclonal antibodies have emerged as a vital instrument in medical care provision and scientific research.

Market Introduction:

Multiple copies of a single antibody are created in a lab to create monoclonal antibodies, a type of immunotherapy. Several monoclonal antibodies have received FDA approval for treating inflammatory, cancerous, and other conditions. The prominent factor driving the monoclonal antibodies market is the growing number of chronic diseases like cancer, heart disease, and others (mAbs). It is expected that more people will use mAb treatments for targeted therapies and that patients and doctors will learn more about them, which will help in the market’s growth. Also, the COVID-19 pandemic has led to the development of different mAbs that fight the SARS-CoV-2 virus, which has made it easier to grow the market. Due to their safety and effectiveness, mAbs are a possible way to deal with COVID-19. Many of these antibodies have emergency use authorizations (EUAs) from the U.S. FDA. For example, the US Food and Drug Administration gave Eli Lilly's bebtelovimab a EUA (European Union Authorization) in February 2022 to treat COVID-19 patients at risk of serious illness or who may need to go to the hospital (FDA). The United States Department of Health and Human Services has also said they will give away at least 600,000 free courses of bebtelovimab. They may also buy 500,000 more doses shortly. This will make it possible for monoclonal antibodies (mAbs) and related industries to grow in new ways. There have been a lot of new product releases and approvals in this industry as a direct result of the key advantages that mAb treatments have over older therapies in terms of their specificity, effectiveness, and ease of use.

Monoclonal Antibodies Market Size

Get an overview of this study by requesting a free sample

Recent Development
  • In February 2022, Bebtelovimab is an antibody that can reduce the effects of      Omicron variant     . Eli Lilly and Company announced that the Food and Drug Administration (FDA) of the United States had given bebtelovimab an Emergency Use Authorization (EUA). Bebtelovimab is an IgG1 monoclonal antibody (mAb) that targets the spike protein of SARS-CoV-2.
  • In January 2022, Lonza and HaemaLogiX Ltd. (HaemaLogiX) made a deal for Lonza to make the next clinical batch (cGMP) of KappaMab, HaemaLogiX's most important treatment candidate for multiple myeloma. KappaMab is a monoclonal antibody that binds to kappa myeloma antigen (KMA), found on the cells' surface.

Market Dynamics:

Drivers

Increasing regulatory approvals- It is expected that more monoclonal antibodies will be approved by regulatory agencies, making it easier for new medicines to come out for treatments. This is expected to help the market’s growth over the forecast period. For example, in 2018, Chugai Pharmaceutical Co., Ltd., now a subsidiary of Roche Holding AG, announced that the US Food and Drug Administration had given its medicine, Satralizumab, Breakthrough Therapy Designation. In May 2018, the US Food and Drug Administration (FDA) approved Johnson & Johnson's Darzalex (daratumumab) monoclonal antibody to be used with Velcade (bortezomib), melphalan and prednisone to treat newly diagnosed multiple myeloma patients who are not candidates for autologous stem cell transplantation (ASCT).

Restraints:

High cost- The high cost of monoclonal antibodies is expected to hinder the market’s growth. The high cost of making monoclonal antibodies is the main reason why they are still only used in industrialised countries and not in emerging or developing countries. The loss of patents by corporations also restraints the market’s growth.

Opportunities:

Growing research and investment- The increasing focus on research and development activities is expected to provide lucrative growth opportunities for the market’s growth over the forecast period. Along with increased government funding for the development of the monoclonal antibodies industry, market participants have increased their spending on the research and development of novel pharmaceuticals and their clinical trials, which provides opportunities for the market’s growth over the forecast period.

Challenges:

Stringent regulatory issues- Stringent regulatory issues related to drug approvals and drug testing is a challenge to the market’s growth. Furthermore, several countries do not allow the testing of drugs on humans before the proper approval, which challenges the market’s growth. The capacity of monoclonal antibodies market products to treat previously incurable diseases has cleared the way for the release of ground-breaking medications on the market; however, there are several regulatory compliances attached to these drugs, which challenges the market’s growth.

Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the largest market for the global monoclonal antibodies market, with a 35.2% share of the market revenue in 2023.

North America currently dominates the monoclonal antibodies market because there is a well-established healthcare system, a high level of patient awareness, and a rise in cancer research opportunities. The market is also expected to grow because of important competitors like Pfizer Inc., Amgen Inc., Merck & Co., and others. Market growth is also expected to be helped by the government spending more money on cancer research.

The Asia Pacific is expected to be the fastest-growing region because people have more money to spend, more people can use monoclonal antibody cancer therapies, and medical care is getting more attention.

North America Region Monoclonal Antibodies Market Share in 2023 - 35.2%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Production method segment analysis

The product method segment is divided into in vivo and in vitro. The in vivo segment dominated the market, with a market share of around 55.2% in 2023. In vivo production method is cheaper to make in large quantities and less likely to get contaminated by antigens from other organisms, propelling the segment’s growth. Also, the type of production is limited by differences in the hybridoma, which can cause antibodies to become denatured or inactive and slow the segment's growth. These differences can also make making a certain type of product hard.

Source segment analysis

The source segment is divided into chimeric, human, humanized, and murine.  Over the forecast period, the human segment is expected to grow at the fastest CAGR of 16.7%. The human segment dominated the market, with a market share of around 30.2% in 2023. Human monoclonal antibodies are better than chimeric or humanized mAbs because they can better control effector functions and are less likely to cause an immune response.

End-User segment analysis

The end-user segment is divided into hospitals, research institutes, and others. The hospital segment dominated, with a market share of around 38% in 2023. Monoclonal antibodies (mAbs) are being used more and more to treat cancer in hospitals. The segment will likely be the most important during the forecast period because of several factors. These include the fact that healthcare costs are increasing worldwide, that patients are becoming more aware of their health, and that hospitals in developed countries have more modern infrastructure.

Some of the Key Market Players:
  • Novartis AG
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Merck & Co., Inc.
  • Daiichi Sankyo Company, Limited
  • Abbott Laboratories
  • AstraZeneca plc
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.

Report Description:

Attribute Description
Market Size Revenue (USD Billion)
Market size value in 2023 USD 209.44 Billion
Market size value in 2033 USD 650.49 Billion     
CAGR (2024 to 2033) 12%
Historical data 2020-2022
Base Year 2023
Forecast 2024-2033
Regional Segments North America, Asia Pacific, Europe, Latin America, Middle East and Africa
Segments Production Method, Source, End-User

Frequesntly Asked Questions

As per The Brainy Insights, the size of the monoclonal antibodies market was valued at USD 209.44 billion in 2023 to USD 650.49 billion by 2033.

The global monoclonal antibodies market is growing at a CAGR of 12.0% during the forecast period 2024-2033.

North America emerged as the largest market for monoclonal antibodies.

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Production Method
          4.3.2. Market Attractiveness Analysis By Source
          4.3.3. Market Attractiveness Analysis By End Users
          4.3.4. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Increasing regulatory approvals
    5.3. Restraints
          5.3.1. High cost
    5.4. Opportunities
          5.4.1. Growing research and investment
    5.5. Challenges
          5.5.1. Stringent regulatory issues

6. Global Monoclonal Antibodies Market Analysis and Forecast, By Production Method
    1.1. Segment Overview
    1.2. In Vivo
    1.3. In Vitro

7. Global Monoclonal Antibodies Market Analysis and Forecast, By Source
    1.4. Segment Overview
    1.5. Chimeric
    1.6. Human
    1.7. Humanized
    1.8. Murine

8. Global Monoclonal Antibodies Market Analysis and Forecast, By End Users
    1.9. Segment Overview
    1.10. Hospitals
    1.11. Research Institutes
    1.12. Others

9. Global Monoclonal Antibodies Market Analysis and Forecast, By Regional Analysis
    1.13. Segment Overview
    1.14. North America
          1.14.1. U.S.
          1.14.2. Canada
          1.14.3. Mexico
    1.15. Europe
          1.15.1. Germany
          1.15.2. France
          1.15.3. U.K.
          1.15.4. Italy
          1.15.5. Spain
    1.16. Asia-Pacific
          1.16.1. Japan
          1.16.2. China
          1.16.3. India
    1.17. South America
          1.17.1. Brazil
    1.18. Middle East and Africa
          1.18.1. UAE
          1.18.2. South Africa

10. Global Monoclonal Antibodies Market-Competitive Landscape
    1.1. Overview
    1.2. Market Share of Key Players in Global Monoclonal Antibodies Market
          1.2.1. Global Company Market Share
          1.2.2. North America Company Market Share
          1.2.3. Europe Company Market Share
          1.2.4. APAC Company Market Share
    1.3. Competitive Situations and Trends
          1.3.1. Product Launches and Developments
          1.3.2. Partnerships, Collaborations, and Agreements
          1.3.3. Mergers & Acquisitions
          1.3.4. Expansions

11. Company Profiles
    1.1. Pfizer Inc
          1.1.1. Business Overview
          1.1.2. Company Snapshot
          1.1.3. Company Market Share Analysis
          1.1.4. Company Product Portfolio
          1.1.5. Recent Developments
          1.1.6. SWOT Analysis
    1.2. GlaxoSmithKline plc
          1.2.1. Business Overview
          1.2.2. Company Snapshot
          1.2.3. Company Market Share Analysis
          1.2.4. Company Product Portfolio
          1.2.5. Recent Developments
          1.2.6. SWOT Analysis
    1.3. Amgen Inc.
          1.3.1. Business Overview
          1.3.2. Company Snapshot
          1.3.3. Company Market Share Analysis
          1.3.4. Company Product Portfolio
          1.3.5. Recent Developments
          1.3.6. SWOT Analysis
    1.4. Merck & Co., Inc.
          1.4.1. Business Overview
          1.4.2. Company Snapshot
          1.4.3. Company Market Share Analysis
          1.4.4. Company Product Portfolio
          1.4.5. Recent Developments
          1.4.6. SWOT Analysis
    1.5. Novartis AG
          1.5.1. Business Overview
          1.5.2. Company Snapshot
          1.5.3. Company Market Share Analysis
          1.5.4. Company Product Portfolio
          1.5.5. Recent Developments
          1.5.6. SWOT Analysis
    1.6. Daiichi Sankyo Company, Limited
          1.6.1. Business Overview
          1.6.2. Company Snapshot
          1.6.3. Company Market Share Analysis
          1.6.4. Company Product Portfolio
          1.6.5. Recent Developments
          1.6.6. SWOT Analysis
    1.7. Abbott Laboratories
          1.7.1. Business Overview
          1.7.2. Company Snapshot
          1.7.3. Company Market Share Analysis
          1.7.4. Company Product Portfolio
          1.7.5. Recent Developments
          1.7.6. SWOT Analysis
    1.8. AstraZeneca plc
          1.8.1. Business Overview
          1.8.2. Company Snapshot
          1.8.3. Company Market Share Analysis
          1.8.4. Company Product Portfolio
          1.8.5. Recent Developments
          1.8.6. SWOT Analysis
    1.9. Eli Lilly And Company
          1.9.1. Business Overview
          1.9.2. Company Snapshot
          1.9.3. Company Market Share Analysis
          1.9.4. Company Product Portfolio
          1.9.5. Recent Developments
          1.9.6. SWOT Analysis
    1.10. Johnson & Johnson Services, Inc.
          1.10.1. Business Overview
          1.10.2. Company Snapshot
          1.10.3. Company Market Share Analysis
          1.10.4. Company Product Portfolio
          1.10.5. Recent Developments
          1.10.6. SWOT Analysis

List of Table

1. Global Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

2. Global In Vivo, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion) 

3. Global In Vitro, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion) 

4. Global Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

5. Global Chimeric, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion) 

6. Global Human, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion) 

7. Global Humanized, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion) 

8. Global Murine, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion) 

9. Global Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

10. Global Hospitals, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion)

11. Global Research Institutes, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion)

12. Global Others, Monoclonal Antibodies Market, By Region, 2020-2033 (USD Billion)

13. North America Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

14. North America Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

15. North America Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

16. U.S. Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

17. U.S. Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

18. U.S. Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

19. Canada Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

20. Canada Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

21. Canada Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

22. Mexico Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

23. Mexico Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

24. Mexico Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

25. Europe Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

26. Europe Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

27. Europe Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

28. Germany Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

29. Germany Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

30. Germany Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

31. France Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

32. France Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

33. France Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

34. U.K. Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

35. U.K. Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

36. U.K. Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

37. Italy Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

38. Italy Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

39. Italy Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

40. Spain Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

41. Spain Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

42. Spain Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

43. Asia Pacific Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

44. Asia Pacific Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

45. Asia Pacific Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

46. Japan Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

47. Japan Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

48. Japan Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

49. China Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

50. China Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

51. China Monoclonal Antibodies  Market, By End Users, 2020-2033 (USD Billion)

52. India Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

53. India Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

54. India Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

55. South America Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

56. South America Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

57. South America Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

58. Brazil Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

59. Brazil Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

60. Brazil Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

61. Middle East and Africa Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

62. Middle East and Africa Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

63. Middle East and Africa Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

64. UAE Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

65. UAE Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

66. UAE Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

67. South Africa Monoclonal Antibodies Market, By Production Method, 2020-2033 (USD Billion)

68. South Africa Monoclonal Antibodies Market, By Source, 2020-2033 (USD Billion)

69. South Africa Monoclonal Antibodies Market, By End Users, 2020-2033 (USD Billion)

List of Figures 

1. Global Monoclonal Antibodies  Market Segmentation

2. Global Monoclonal Antibodies  Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Monoclonal Antibodies Market Attractiveness Analysis By Production Method

9. Global Monoclonal Antibodies Market Attractiveness Analysis By Source

10. Global Monoclonal Antibodies Market Attractiveness Analysis By End Users

11. Global Monoclonal Antibodies Market Attractiveness Analysis By Region

12. Global Monoclonal Antibodies Market: Dynamics

13. Global Monoclonal Antibodies Market Share By Production Method (2023 & 2033)

14. Global Monoclonal Antibodies Market Share By Source (2023 & 2033)

15. Global Monoclonal Antibodies Market Share By End Users (2023 & 2033)

16. Global Monoclonal Antibodies Market Share By Regions (2023 & 2033)

17. Global Monoclonal Antibodies Market Share By Company (2023)

This study forecasts global, regional, and country revenue from 2020 to 2033. Brainy Insights has segmented the global monoclonal antibodies market based on the below-mentioned segments:

Global Monoclonal Antibodies Market by Production Method:

  • In Vivo
  • In Vitro

Global Monoclonal Antibodies Market by Source:

  • Chimeric
  • Human
  • Humanized
  • Murine

Global Monoclonal Antibodies Market by End Users:

  • Hospitals
  • Research Institutes
  • Others

Global Monoclonal Antibodies Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date